Massachusetts And New Orleans
Reduction of Geographic Miss and Bail-out Stenting Observed With Highly Visible PROMUS Element Stent
NATICK, Massachusetts and NEW ORLEANS, April 5, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced
12-month results from the pivotal PLATINUM Workhorse trial comparing the
safety and effectiveness of the PROMUS Element(TM) Everolimus-Eluting
Platinum Chromium (PtCr) Coronary Stent System to the PROMUS(R)
Everolimus-Eluting Coronary Stent System.
